Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.
paper
Cited
Public
Unavailable
- Authors
- Bymaster, F P; Felder, C C
- Year
- 2002
- Journal
- Molecular psychiatry
- PMID
- 11986996
- DOI
- 10.1038/sj.mp.4001019
The evidence for the involvement of cholinergic muscarinic receptors in mania and depression is reviewed. Small pilot trials with cholinesterase inhibitors and muscarinic agonists suggest that stimulation of muscarinic receptors may produce an antimanic effect, possibly by activation of muscarinic M(4) receptors. It is concluded that it is not likely that currently used mood stabilizers, such as lithium, valproic acid and carbamazepine, work directly through muscarinic receptor mechanisms. Furthermore, the evidence indicates that antipsychotic agents used for mania are working through the common mechanism of antagonism of dopamine D(2) receptors, and interactions with muscarinic receptors do not play a key role. Finally, it is hypothesized that olanzapine has robust antimanic activity, due to blockade of dopamine D(2) receptors and antagonism of other monoaminergic receptors. Olanzapine may normalize mood due to antidepressant-like activities, such as 5-HT(2A) receptor antagonism and increasing cortical norepinephrine and dopamine.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. | 2006 | 17373405 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder? | McIntyre RS | — | 2025 | → |
| G protein-coupled receptors in drug discovery for neurological and psychiatric disorders: therapeutic targets, mechanisms, and future prospects. | Zhang M et al. | — | 2025 | → |
| Muscarinic acetylcholine receptor agonists in bipolar disorder. | González-Campos M et al. | — | 2025 | → |
| Neurobiological mechanisms and recent advances in drug-based therapeutics in depression. | Ahmadnia H et al. | — | 2025 | → |
| PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [<sup>11</sup>C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator. | Belov V et al. | — | 2024 | → |
| Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data. | Fountoulakis KN et al. | — | 2023 | → |
| Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder. | Amare AT et al. | — | 2023 | → |
| Basal Forebrain Cholinergic Innervation Induces Depression-Like Behaviors Through Ventral Subiculum Hyperactivation. | Yu N et al. | — | 2023 | → |
| Reviewing the mitochondrial dysfunction paradigm in rodent models as platforms for neuropsychiatric disease research. | van Rensburg DJ et al. | — | 2022 | → |
| Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders? | Gammon D et al. | — | 2021 | → |
| Cortical biometals: Changed levels in suicide and with mood disorders. | Dean B et al. | — | 2019 | → |
| Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. | Romano A et al. | — | 2017 | → |
| Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. | Gibbons AS et al. | — | 2016 | → |
| The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. | Pytka K et al. | — | 2016 | → |
| Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. | Drago A et al. | — | 2015 | → |
| The muscarinic system, cognition and schizophrenia. | Carruthers SP et al. | — | 2015 | → |
| The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. | Fountoulakis KN et al. | — | 2015 | → |
| Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? | Sharma H et al. | — | 2015 | → |
| Acute mood effect of donepezil in young, healthy volunteers. | Pompeia S et al. | — | 2013 | → |
| Evaluation of acetylcholinesterase in an animal model of mania induced by D-amphetamine. | Varela RB et al. | — | 2013 | → |
| Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder. | Modi HR et al. | — | 2013 | → |
| Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. | Weston-Green K et al. | — | 2013 | → |
| Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. | Scarr E | — | 2012 | → |
| Receptor targets for antidepressant therapy in bipolar disorder: an overview. | Fountoulakis KN et al. | — | 2012 | → |
| Bipolar affective disorder, type II, apparently precipitated by donepezil. | Collins C et al. | — | 2011 | → |
| The neural control of mood: the possible role of the adrenergic system in the medulla. | Smythies J | — | 2011 | → |
| The role of the aminergic systems in the pathophysiology of bipolar disorder. | Walderhaug E et al. | — | 2011 | → |
| Projection-specific neuromodulation of medial prefrontal cortex neurons. | Dembrow NC et al. | — | 2010 | → |
| Protective role of lithium during aluminium-induced neurotoxicity. | Bhalla P et al. | — | 2010 | → |
| A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. | Ghaemi SN et al. | — | 2009 | → |
| Bipolar disorder and mechanisms of action of mood stabilizers. | Rapoport SI et al. | — | 2009 | → |
| Depression and antidepressants: molecular and cellular aspects. | Lanni C et al. | — | 2009 | → |
| Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. | Wang JF et al. | — | 2009 | → |
| Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats. | Basselin M et al. | — | 2008 | → |
| Computer-based de novo design, synthesis, and evaluation of boronic acid-based artificial receptors for selective recognition of dopamine. | Jin S et al. | — | 2008 | → |
| Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. | Shekhar A et al. | — | 2008 | → |
| Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. | Uchida S et al. | — | 2007 | → |
| No evidence for association between 19 cholinergic genes and bipolar disorder. | Shi J et al. | — | 2007 | → |
| Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. | Weikop P et al. | — | 2007 | → |
| A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. | Eden Evins A et al. | — | 2006 | → |
| Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency. | Gautam D et al. | — | 2006 | → |
| Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. | Basselin M et al. | — | 2006 | → |
| Chronic lithium chloride administration to rats elevates glucose metabolism in wide areas of brain, while potentiating negative effects on metabolism of dopamine D2-like receptor stimulation. | Basselin M et al. | — | 2006 | → |
| Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. | Grucza RA et al. | — | 2006 | → |
| Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. | DelBello MP et al. | — | 2006 | → |
| Olanzapine: a 5-year perspective. | Littrell KH et al. | — | 2006 | → |
| The cholinergic system in Down's syndrome. | Fodale V et al. | — | 2006 | → |
| The role of the extrapersonal brain systems in religious activity. | Previc FH | — | 2006 | → |
| Chronic lithium administration to rats selectively modifies 5-HT2A/2C receptor-mediated brain signaling via arachidonic acid. | Basselin M et al. | — | 2005 | → |
| Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. | Basselin M et al. | — | 2005 | → |
| Genetic tests of biologic systems in affective disorders. | Hattori E et al. | — | 2005 | → |
| Gi/Go protein-dependent presynaptic mechanisms are involved in clozapine-induced down-regulation of tyrosine hydroxylase in PC12 cells. | Tejedor-Real P et al. | — | 2005 | → |
| Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism. | Ichikawa J et al. | — | 2005 | → |
| Serotonin receptors: their key role in drugs to treat schizophrenia. | Meltzer HY et al. | — | 2003 | → |